Table 1:
Adrenal SBRT studies reviewed in the study. Ones included in the adrenal tumor control probability model are shown in Figure 1.
| Author (citation) | No. of Patients | Median FU (m) [range] | No. of Lesions | Primary Site | Volumes (mm) | Median Total Dose (Gy) [range] | No. of Fractions | Local Control | Overall Survival | Rx type | Target Dose Coverage | GTV size (cc) [range] |
PTV size (cc) [range] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *Ahmed, 2013 (7) | 13 | 12.3 [3.1–18] | 13 | Lung, Kidney, Skin, Other | GTV=CTV PTV=ITV+5 | 45 [33.75–60] | 5 (all) | 12.3mo-100% | 12 mo- 62.9% | NR | NR | NR | 88.4 [37.7–379.6] |
| Barney, 2012 (8) | 6 (subgroup of 50 abdo/pelvic mets:numbers quoted are for entire patient cohort). | 12 [2–28] | 6 | GI, Lung, Kidney, Other | GTV=CTV PTV=ITV+5 | 45 [20–60] | 5 [1–5] | 6 mo- 98%; 12 mo-87% | 6 mo- 90% 12 mo- 62% | 95% IDL | 99% target received at least 90% dose | NR | NR |
| *Casamassima, 2012 (9) | 48 | 16.2 [3–63] | 48 | Lung, Colon, Melanoma, Other | GTV=CTV PTV=ITV+3 | 36 [21.69–54.09] | 3 [1–3] | 12 mo- 90% 24 mo- 90% | 12 mo- 39.7% 24 mo- 14.5% | 70% IDL | NR | 103.4 [6.6–497] | NR |
| *Chawla, 2009 (5) | 30 | 9.8 [3.2–28.3] | 35 | Lung, Liver, Breast, Other | GTV=CTV PTV=CTV+7–10 | 40 [16–50] | 10 [4–16] | 6 mo- 91% 12 mo- 55% 24 mo- 27% | 12 mo- 44% 24 mo- 25% | 100% IDL | 80% to PTV | 18.6 [7.5–156] | NR |
| *Guiou, 2012 (10) | 9 | 7.3 (mean) [0–26] |
10 | Lung | ITV PTV=ITV+ expansion | 25 [20–37.5] | 5 (all) | 12 mo- 44% 24 mo- 44% | 12 mo- 52% 24 mo- 13% | NR | NR | 163 [22.3–599.7] | 306.62 [127.5–953.6] |
| Holy, 2011 (11) | 18 | 12 [2–61] | 18 | Lung | CTV=GTV+2 PTV=CTV+5–10 | 40 [24–40] | 5 [3–6] | Median PFS- 4.2 mo | Median- 21 mo | 100% IDL | ~100% | NR | 176 [20–422] |
| *Katoh, 2008 (12) | 9 | 16 [5–21] | 10 | Lung, Prostate, Kidney, Liver | CTV=GTV+3 PTV=CTV+5 | 48 [30–48] | 8 (all) | 12 mo- 100% | 12 mo- 78% | iso | 80% to PTV | NR | NR |
| Oshiro, 2011 (27) | 19 (11 underwent hypofractionation and 8 underwent conventional fractionation) |
10.1 [0.7–87.8] | 19 | Lung | CTV=GTV PTV=CTV+5–10 | 45 [30–60] | 10 [1–27] | NR | For synchronous mets; 12 mo- 55.6% 24 mo- 33.4% 60 mo- 22.3% Metachronous mets: 12 mo-83.3% 24 mo and 60 mo- 55.6% |
NR | NR | NR | NR |
| *Rudra, 2011 (13) | 10 | 14.9 [5–45.8] | 13 | Lung, Kidney | ITV PTV=ITV+5–10 | 36 [24–50] | 3 [3–10] | 12 mo- 73% | 12 mo- 90% | 80–90% IDL | V95%>95% | NR | NR |
| *Scorsetti, 2012 (14) | 34 | 41 [12–75] | 36 | Lung, Melanoma, Other | CTV=GTV+3 PTV=CTV+5 | 32 [20–45] | 4 [4–18] | 12 mo- 66% 24 mo- 32% | 24 mo- 53% | NR | NR | NR | NR |
| *Torok, 2011 (15) | 7 | 14 [1–60] | 9 | Lung, Liver | GTV=CTV PTV=ITV | 16 (for 5 lesions) [10–22] 27 (for 4 lesions) [24–36] | 16 Gy in 1 fx 27 Gy in 3 fx | 12 mo- 63% | Median- 8 mo | 1fx: 80% 3fx: 94% | 86% | 63.8 [5–123.6] |
NR |
| Desai, 2015 (22) | 14 | NR | 14 | Lung, Renal, Other | NR | 25 [13–30] | 3 [1–5] | NR | Median- 7 mo | NR | NR | NR | NR |
| *Chance, 2016 (18) | 43 | 16 [3–94] |
49 | Lung, Ovary, Esophagus, Other | ITV PTV=ITV+3–5 | 60 [40–70] | 10 [4–15] | 12 mo- 74% 24 mo- 57% |
12 mo- 65% 24mo- 42% |
95% IDL | 97% (median) | 13 [3–90] |
41 [11–262] |
| *Franzese, 2017 (26) | 46 | 7.6 | Lung, Other | CTV PTV = CTV + 5 | 40 (all) | 4 (all) | 12 mo- 66% (±12%) 24 mo 41% (±16%) |
12 mo- 87.6% | V95%>90% (for PTV) | V95%>90% | NR | 63 (mean) (±34) | |
| *Gamsiz, 2015 (16) | 15 | 16 | 17 | Lung | GTV=CTV (DIBH) PTV=CTV+3–5 | 30 (all) | 3 (all) | 16 mo- 86.7% | 16 mo- 33% | 90–100% IDL | NR | 28.4 (mean) [6.6–101.5] | 57.4 (mean) [16.5–143.8] |
| Li, 2013 (23) | 26 | NR | 26 | Various | PGTV=GTV + 3 CTV=GTV +8 PTV=CTV+2–3 | 43 [30–50] | 5 [3–5] | NR | Median- 17 mo | Median- 70% IDL (58–80%) | 95% | NR | NR |
Abbreviations: No. (Number); Gy (Gray); NR (not reported); mo (months); PFS (progression-free survival); fx (fraction); DIBH (deep inspiration breath hold);
*
studies used in TCP model